Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?
Pfizer's post-COVID comeback is still only in the early stages.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
